Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of MFC51123 (Diclofenac + Menthol) for Skin Sensitization
NCT02192203Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diclofenac sodium + menthol in pain, inflammation and sprains and strains (4 arms), sponsored by GSK. Primary endpoint: Skin irritation at 30 days. Started Apr 2014; status: completed.
02
Drugs
diclofenac sodium + menthol
03
Conditions
paininflammationsprains and strains
Beyond the preview
Go deeper on NCT02192203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192203.